MENU

HUM Humana Forecast, Technical & Fundamental Analysis

Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program... Show more

A.I.Advisor
Nov 02, 2026

Humana (HUM) Stock Forecast: Can a Medicare Advantage Ratings Rebound Power a 2028 Margin Turnaround?

Key Takeaways

  • Star Ratings recovery is the central forward catalyst. Humana reported that 95% of its Medicare Advantage members are in plans rated four stars or higher for 2027, up sharply from the prior year, a swing analysts expect to drive roughly $4.8 billion in quality bonus payments in 2028.
  • Margin restoration is the multiyear story. Management is reshaping its plan portfolio toward higher-performing markets and targeting a sustainable roughly 3% pre-tax margin in Medicare Advantage by 2028, following an earnings reset guided by a 2026 adjusted EPS (earnings per share) floor of at least $9.00.
  • Analyst sentiment has turned more constructive. Firms including Baird, Barclays, Oppenheimer, and Raymond James have raised price targets or upgraded ratings, reflecting greater confidence in a 2028 earnings recovery, though several firms remain at Hold pending execution.
  • Macro and policy sensitivity remains high. Medicare Advantage reimbursement decisions, medical cost trends, potential GLP-1 drug coverage costs, and the political and regulatory climate can all shift the trajectory of government-funded managed care margins.
  • Execution risk is the key offset. How much of the bonus upside is reinvested into richer benefits to win members, versus flowing through to earnings, will determine whether improved ratings translate into durable profitability.
  • Explore more on this ticker. Get the latest on Humana's Major News and Today's Price Move, review analyst Price Targets, and track upcoming Earnings.
  • Automate your research. Explore Trending AI Robots to see AI-driven trading strategies monitoring tickers like HUM.

Strategic Positioning and Competitive Outlook

Humana is one of the largest U.S. health insurers and a leading player in Medicare Advantage, the privately administered alternative to traditional Medicare that covers millions of seniors. Its scale in senior-focused coverage, combined with an integrated care-delivery arm — the CenterWell brand, which spans primary care, home health, and pharmacy — gives it a differentiated ability to manage medical costs through value-based care models.

The company's medium-term positioning hinges on rebuilding the quality of its plan portfolio. After a sharp ratings decline across 2025 and 2026, the recovery of its large contracts, including the roughly two-million-member H5216 plan back to four stars, restores eligibility for quality bonus payments and improves how plans appear to prospective members during the annual open-enrollment period. This strengthens Humana's competitive footing at a moment when some large rivals face their own ratings slippage.

Structurally, Humana is pruning less profitable markets — with plan exits expected to affect roughly 600,000 members in 2027 — and concentrating on higher-performing regions and special-needs plans. A new joint venture with BlackRock's HPS Investment Partners to manage nearly 150 CenterWell senior primary-care clinics is designed to reduce balance-sheet liabilities and add financial flexibility, supporting the broader effort to fund growth while restoring margins.

Major Catalysts Ahead

The most significant near-term events center on execution of the ratings-driven recovery. Humana's December 10, 2026 investor update is a key opportunity for management to quantify the expected 2028 quality-bonus impact, outline the 2027 benefit and bid strategy, and update its path toward the 2028 margin target. Clarity on how much bonus revenue is retained versus reinvested will heavily influence sentiment.

Quarterly earnings remain pivotal. The company has affirmed a 2026 adjusted EPS floor of at least $9.00 while revising GAAP (Generally Accepted Accounting Principles) EPS guidance lower, underscoring that near-term results still carry the drag of prior-year ratings. Investors will watch medical cost trends and membership retention during the 2027 open-enrollment season, which runs through early December.

Analyst rating trends have shifted from caution to a more balanced, increasingly constructive stance. The consensus profile now skews toward Buy or Moderate Buy, with an average price target around the mid-$400s. Recent moves include Baird's upgrade to Outperform with a $596 target, Barclays' $582 target tied to a 93% bonus mix, Oppenheimer's $525 target, and Raymond James' upgrade to Outperform with a $520 target. These revisions reflect rising conviction in a 2028 earnings inflection, though a meaningful minority of analysts retain Hold ratings, reflecting execution uncertainty and the binary nature of future ratings cycles.

Industry and Macroeconomic Forces

Humana's trajectory is closely tied to government health policy and the economics of managed care. Medicare Advantage reimbursement rates, set annually by the Centers for Medicare and Medicaid Services (CMS), directly influence plan pricing, benefit richness, and margins. Proposals for flat or constrained rate updates, or expanded coverage mandates such as GLP-1 weight-loss drugs, could pressure profitability across the sector.

Medical cost trends are equally important. Elevated utilization, hospital pricing, and prescription-drug inflation can compress margins if they outpace government payment growth. Conversely, the moderating cost-trend environment some analysts cite is a tailwind for margin recovery. Interest rates and inflation also shape the financing of the CenterWell clinic network and capital-allocation decisions, while broader demographic aging underpins long-term demand for senior-focused care.

Regulatory scrutiny remains a live risk, including congressional inquiries into Affordable Care Act premium-subsidy practices and ongoing debate over risk-adjustment and coding rules. Political outcomes can influence reimbursement philosophy, making the policy cycle a structural swing factor for the entire managed-care group.

Trend Prediction Engine

For investors tracking how these catalysts may shape near-term price action, Tickeron's Trend Prediction Engine offers an AI-powered forecasting tool designed to help identify whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the next week or month. It helps users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments, with searchable categories, historical context, and alert-oriented functionality. As you monitor Humana's unfolding story, the Trend Prediction Engine can serve as a complementary signal alongside fundamental analysis.

2026 Outlook and Long-Term Themes to Watch

Looking toward 2026 and beyond, Humana's investment narrative centers on a multiyear earnings recovery rather than near-term results. The 2027 Star Ratings improvement sets the stage for an estimated $4.8 billion in quality bonus payments in 2028, and several analysts model adjusted EPS reaching the mid-$30s by 2028 — a sharp rebound from the 2026 floor of at least $9.00. The credibility of that path depends on disciplined bidding, controlled medical costs, and member retention through the 2027 enrollment cycle.

Long-term themes include the strategic expansion of CenterWell's integrated care model, which positions Humana to capture value as care shifts toward primary-care-led, home-based delivery. Cost-structure evolution — including operating-cost reductions and the HPS clinic joint venture — is central to margin sustainability. Competitive threats from UnitedHealth, CVS Health's Aetna, and Elevance Health remain significant, as do regulatory developments around reimbursement and coding practices.

Capital-allocation priorities are another area to monitor: a disciplined buyback program and balance-sheet flexibility could support per-share value as earnings recover. While consensus expectations have become more optimistic, the wide spread between the lowest and highest price targets reflects genuine disagreement over how much of the ratings-driven upside converts into durable profitability — keeping execution, cost trends, and future ratings cycles at the center of the debate.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Interact to see
Advertisement
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published Earnings

HUM is expected to report earnings to rise 1,020.00% to -784 cents per share on February 03

Humana HUM Stock Earnings Reports
Q4'26
Est.
$-7.84
Q3'26
Beat
by $0.33
Q2'26
Beat
by $0.38
Q1'26
Beat
by $0.11
Q4'25
Beat
by $0.04
The last earnings report on November 06 showed earnings per share of -69 cents, beating the estimate of -102 cents. With 315.88K shares outstanding, the current market capitalization sits at 52.08B.
A.I.Advisor
published Dividends

HUM is expected to pay dividends on November 27, 2026

Humana HUM Stock Dividends
A quarterly dividend of $0.88 per share will be paid with a record date of November 27, 2026, and an ex-dividend date of October 30, 2026. The last dividend of $0.88 was paid on July 31. Read more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
USAR8.160.09
+1.12%
USA Rare Earth Inc
MEDP653.94-2.90
-0.44%
Medpace Holdings
NIXX0.18N/A
-1.61%
Nixxy, Inc.
RXT2.92-0.09
-2.99%
Rackspace Technology
GRO1.65-0.11
-6.25%
Brazil Potash Corp

HUM and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, HUM has been closely correlated with UNH. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if HUM jumps, then UNH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HUM
1D Price
Change %
HUM100%
+1.42%
UNH - HUM
67%
Closely correlated
+0.58%
ELV - HUM
56%
Loosely correlated
-0.05%
CVS - HUM
51%
Loosely correlated
-0.49%
CNC - HUM
48%
Loosely correlated
+1.42%
CI - HUM
36%
Loosely correlated
+0.25%
More

Groups containing HUM

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HUM
1D Price
Change %
HUM100%
+1.42%
HUM
(2 stocks)
92%
Closely correlated
+1.00%
A.I. Advisor
published General Information

General Information

a company offers health insurance coverage and related services

Industry ManagedHealthCare

Industry
Managed Health Care
Address
101 East Main Street
Phone
+1 502 580-1000
Employees
67060
Web
https://www.humana.com